Berenberg downgrades Brenntag stock to Hold on geopolitical concerns

Berenberg downgraded Brenntag AG from Buy to Hold, significantly reducing its price target to EUR55 from EUR71, anticipating a lower FY25 guidance range due to disappointing performance, geopolitical uncertainty, and a weak USD. The firm cut its FY25 EBITA estimate to EUR1.05 billion, below Brenntag's current guidance of EUR1.1-1.3 billion. Concurrently, Deutsche Bank also lowered its price target and 2025 EBITA forecast for Brenntag following a soft Q1, although it maintained a Buy rating. Brenntag, while retaining its FY25 EBITA guidance, has hinted at achieving only the lower end, underscoring the challenges from macroeconomic risks and currency headwinds.

Analysis

Brenntag AG is facing a significant negative shift in analyst sentiment, indicating a deteriorating near-term outlook. Berenberg has downgraded the stock to 'Hold' from 'Buy' and executed a material price target reduction to EUR 55.00 from EUR 71.00, citing a confluence of headwinds including disappointing recent performance, geopolitical uncertainty, and a weak US dollar. Critically, Berenberg's revised FY25 EBITA estimate of EUR 1.05 billion now falls below the company's own guidance floor of EUR 1.1 billion. This bearish view is corroborated by Deutsche Bank, which also lowered its price target to EUR 80.00 and cut its 2025 EBITA forecast by 8% to €1,090 million following a weaker-than-expected Q1. While Brenntag has officially maintained its guidance of €1.1 billion to €1.3 billion, it has signaled an expectation to land at the lower end of this range. The alignment of analyst forecast cuts with the company's own cautious commentary suggests a high probability of a formal guidance reduction, challenging the view that the stock is undervalued based on its 15.76x P/E ratio amid rising fundamental risks.

Key Decisions for Investors

• Investors should reassess bullish theses on Brenntag, as multiple analyst downgrades and forecast cuts below the company's guidance range increase the risk profile significantly.
• Closely monitor leading indicators cited by analysts, such as profit warnings from chemical manufacturers, geopolitical developments in the Middle East, and US dollar exchange rate movements, as these could trigger further downward revisions.
• Exercise caution regarding the stock's valuation; while a 15.76x P/E ratio might appear low, it is overshadowed by negative earnings momentum and could represent a potential value trap.
• Anticipate heightened stock volatility and a potential negative catalyst around the next earnings report, where a formal downward revision of the FY25 guidance is now widely expected.